Report
New drug target identified for sickle cell disease and beta thalassemia
Dana-Farber/Harvard researchers discovered BACH2-NRF2 pathway regulating fetal hemoglobin independent of BCL11A. Inhibiting BACH2 increases fetal hemoglobin in red blood cell precursors, offering new therapeutic angles for gene-editing or small-molecule treatments.
TLDR
This discovery provides a distinct target beyond existing approaches like BCL11A, potentially enabling more accessible and cost-effective therapies. New pathways could expand treatment options for millions globally affected by hemoglobinopathies beyond current gene therapy limitations.
Combined views
276
1 Source, first seen 11h ago
9 likes1 comments4 reposts